Comprehensive in vitro antiviral screening against viruses of pandemic potential under antiviral program for pandemics (APP)
Ended Awarded Last action
- Contract number
- 75N93022F00002
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,022,500
Award facts
- Contract value 89% obligated
-
- $2,022,500.00 Current, with exercised options
- $2,278,406.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Driggs, ID, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $375,000 | |
| Original award | $1,647,500 |
About this award
This federal contract award, valued at $2,278,406.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Utah State University (USU) for comprehensive in vitro antiviral screening against viruses of pandemic potential under the Antiviral Program for Pandemics (APP). The contract is a delivery order under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite delivery/indefinite quantity (IDIQ) contract vehicle. As a public research university and 1862 land-grant institution, USU has significant expertise in providing specialized laboratory and technical services to federal agencies across multiple domains, including environmental sciences, engineering, agriculture, and biological research. The contract does not have a set-aside designation, reflecting USU's comprehensive capabilities to support complex, multi-disciplinary federal projects.
Quick answers
Who was awarded contract 75N93022F00002?
75N93022F00002 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 14, 2022.
How much is contract 75N93022F00002 worth?
The government has obligated $2,022,500 on 75N93022F00002. Its potential value, with all options, is $2,278,406.
Is contract 75N93022F00002 an order under another contract?
Yes. 75N93022F00002 is a delivery order under 75N93019D00021, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93022F00002 competed?
The extent of competition for 75N93022F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award